|
Market Closed -
Nasdaq
16:00:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 3.160 USD | -0.63% |
|
-1.25% | -48.62% |
| 07-30 | Myriad Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026 | |
| 07-30 | Myriad Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 302.3 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | -47.28% | - | - |
| Enterprise Value (EV) | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 302.3 | 302.3 | 302.3 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | -44.39% | 0% | 0% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -1.99x | -2.58x | -2.85x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | - | - | - |
| PEG | - | -0x | -0x | 0.2x | -0x | 0x | 0.1x | 0.31x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.39x | 0.37x | 0.34x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.39x | 0.37x | 0.34x |
| EV / EBITDA | 0x | -0x | -0x | 0x | 0x | -5.39x | -7.72x | - |
| EV / EBIT | 0x | -0x | -0x | 0x | 0x | -3.84x | -4.82x | -5.19x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.59 | -1.222 | -1.11 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 777.7 | 821.8 | 877.3 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | -56.03 | -39.17 | - |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | -78.79 | -62.66 | -58.2 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -143.3 | -103.8 | -108.1 |
| Net Debt | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | - | - | - |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 3.160 | 3.160 | 3.160 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 95,650 | - | - |
| Announcement Date | 2/24/22 | 2/28/23 | 2/27/24 | 2/24/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.99x | - | - | -.--% | 302M | |
| -50.29x | 16.41x | -120.35x | -.--% | 21.67B | |
| 18.42x | 2.05x | 8.66x | 1.39% | 10.28B | |
| -82.71x | 12.15x | -111.26x | -.--% | 8.02B | |
| 187.38x | 6.64x | 38.21x | -.--% | 7.24B | |
| 21.36x | 4.24x | 11.72x | - | 6.58B | |
| 22.07x | 7.66x | 17.19x | 2.6% | 6.09B | |
| 22.18x | 3.64x | 11.3x | 1.7% | 4.4B | |
| 17.46x | - | - | 3.51% | 2.81B | |
| Average | 17.10x | 7.54x | -20.65x | 1.15% | 7.49B | |
| Weighted average by Cap. | 3.18x | 9.53x | -45.16x | 0.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
